SCHEMBL888257

SCHEMBL888257

COc1ccc(C(NCCCCCCOP(N)O)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 10/20 0.42
KCNH2 Q12809 1/20 0.42
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
SIGMAR1 Q99720 1/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 1/20 0.36
KCNN4 O15554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL888258 0.86 KIF11 (0.44) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL10309879 0.82 KIF11 (0.45) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL8053146 0.82 KIF11 (0.45) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL12049184 0.82 KIF11 (0.58) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL6302955 0.82 KIF11 (0.45) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL3921295 0.79 KIF11 (0.44) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL8040236 0.79 KIF11 (0.44) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL5391076 0.79 KIF11 (0.61) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL9439820 0.79 KIF11 (0.47) KIF11KCNH2DRD2DRD4DRD3
SCHEMBL6304679 0.79 NPC1 (0.47) KIF11KCNH2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680062-B2 System for delivering therapeutic agents into living cells and cells nuclei Deliversir Ltd. (IL) 2014-03-25 US disclosed
EP-1908829-B1 OLIGONUCLEOTIDE PROBE NAT INST OF ADVANCED IND SCIEN (JP) 2014-01-08 EP disclosed
US-8465921-B2 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders ELITECH HOLDING B.V. (NL) 2013-06-18 US disclosed
US-20110275070-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH PHARMACEUTICALS, INC. 2011-11-10 US disclosed
US-7794945-B2 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders ELITECH HOLDING B.V. (NL) 2010-09-14 US disclosed
EP-1144429-B1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH BIOSCIENCES INC (US) 2009-07-15 EP disclosed
US-7556923-B1 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders EPOCH BIOSCIENCES, INC. (US) 2009-07-07 US disclosed
US-20090048427-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH BIOSCIENCES, INC. (US) 2009-02-19 US disclosed
US-7491857-B2 Oligonucleotide probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2009-02-17 US disclosed
US-20080227968-A1 Oligonucleotide Probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2008-09-18 US disclosed
US-20030113765-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2003-06-19 US disclosed
US-6492346-B1 Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders EPOCH PHARMACEUTICALS, INC. 2002-12-10 US disclosed
US-6472153-B1 COVALENTLY BOUND OLIGONUCLEOTIDE/MINOR GROOVE BINDER/LATENT FLUOROPHORE COMBINATION EPOCH BIOSCIENCES, INC. 2002-10-29 US disclosed
EP-1144429-A3 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS Epoch Pharmaceuticals, Inc. (US) 2002-09-11 EP disclosed
EP-1224332-A1 HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS Epoch Biosciences, Inc. (US) 2002-07-24 EP disclosed
US-6312894-B1 HYBRIDIZATION OF OLIGONUCLEOTIDES AND MINOR GROOVE BINDER COMBINATION; WHERE THE MINOR GROOVE BINDER BINDS IN A NON-INTERCALATING MANNER WITH A HIGHER ASSOCIATION CONSTANT EPOCH PHARMACEUTICALS, INC. 2001-11-06 US disclosed
EP-1144429-A2 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS Epoch Pharmaceuticals, Inc. (US) 2001-10-17 EP disclosed
WO-2001031063-A1 HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS EPOCH BIOSCIENCES, INC. (US) 2001-05-03 WO disclosed
WO-1999051621-A2 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS EPOCH PHARMACEUTICALS, INC. (US) 1999-10-14 WO disclosed
WO-1998034945-A1 TARGETED MODIFICATION OF THE CCR-5 GENE EPOCH PHARMACEUTICALS, INC. (US) 1998-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030113765-A1 Hybridization-triggered fluorescent detection of nucleic acids DDX21, RNGTT, NOP2 KIF11 3303/4885KCNH2 4147/4885DRD2 4653/4885
US-20090048427-A1 HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS DDB1, LIG3, MSH2 KIF11 2447/4885KCNH2 3604/4885DRD2 2116/4885
US-20080227968-A1 Oligonucleotide Probe APEX1, RNGTT, RNASEH1 KIF11 3783/4885KCNH2 3511/4885DRD2 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.